Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
PureTech Health plc is a publicly listed life sciences company focused on founding, building, and advancing biotechnology businesses that develop novel therapies for serious diseases. The company operates primarily within the biotechnology and life sciences innovation industries, with an emphasis on neuroscience, immunology, inflammation, and rare diseases. Rather than functioning as a traditional single-asset biotech, PureTech employs a model centered on creating and scaling internally originated companies, referred to as Founded Entities, which become the primary drivers of long-term value.
PureTech was founded in 2005 and has evolved from a research-focused life sciences incubator into a strategic operator and investor with a portfolio of clinical-stage companies. Over time, the company refined its approach to concentrate capital and expertise on a smaller number of high-conviction programs, many of which have progressed into late-stage clinical development or independent public companies. Its strategic differentiation lies in combining internal scientific innovation, centralized operational infrastructure, and long-term balance sheet investment.
Business Operations
PureTech Health’s operations are organized around its Founded Entities, which are independent biotechnology companies originating from PureTech’s internal research and development efforts. The company generates value primarily through equity ownership in these entities, milestone payments, and, in some cases, royalties or other economic interests tied to product development and commercialization. PureTech does not rely on traditional product sales for revenue and has historically reported variable income based on transaction activity and investment outcomes.
The company conducts operations mainly in the United States and the United Kingdom, maintaining centralized scientific, operational, and capital allocation functions. PureTech retains controlling or significant minority stakes in several Founded Entities and provides shared services, strategic guidance, and access to capital markets. Notable subsidiaries and portfolio companies include Karuna Therapeutics (acquired), Seaport Therapeutics, Vor Bio, and Alivio Therapeutics, though ownership levels and consolidation status vary by entity and over time.
Strategic Position & Investments
PureTech’s strategy centers on advancing a concentrated portfolio of differentiated therapeutic platforms while actively managing capital through company formation, external partnerships, and selective monetization events. A major strategic milestone was the acquisition of Karuna Therapeutics by Bristol Myers Squibb in 2024, which validated PureTech’s incubator model and generated significant capital to be redeployed into new and existing programs.
The company continues to invest in emerging therapeutic modalities, including novel small molecules and brain-penetrant technologies, primarily through newly formed or early-stage Founded Entities. PureTech also evaluates external investments and partnerships that align with its core scientific focus areas. Where applicable, proceeds from exits are reinvested to support long-term growth rather than near-term distribution, reflecting a strategy oriented toward compounding value creation.
Geographic Footprint
PureTech Health is headquartered in Boston, Massachusetts, a major global biotechnology hub, while maintaining a corporate presence in London, United Kingdom, consistent with its status as a UK-incorporated and publicly listed company. Its operational and investment activities are concentrated in North America and Europe, particularly within established life sciences ecosystems.
Through its Founded Entities and investment interests, PureTech’s influence extends internationally, with clinical trials, research collaborations, and development programs conducted across multiple countries. While the company does not operate commercial infrastructure globally, its portfolio companies often engage in multinational development activities aligned with regulatory pathways in the United States, Europe, and other major healthcare markets.
Leadership & Governance
PureTech Health was founded by Daphne Zohar, who continues to shape the company’s long-term vision and strategic direction. Leadership emphasizes scientific rigor, disciplined capital allocation, and the creation of independent companies capable of scaling beyond PureTech’s direct involvement. Governance is structured to support both operational oversight and strategic investment decision-making.
Key members of leadership and governance include:
- Daphne Zohar – Founder & Chief Executive Officer
- Miriana Moro – Chief Financial Officer
- Gareth Morgan – Chair of the Board
The leadership team combines experience in biotechnology, finance, and company building, with a stated focus on long-duration value creation rather than short-term financial performance. Where specific executive responsibilities beyond publicly disclosed roles cannot be independently verified, data is inconclusive based on available public sources.